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cost-eff ective. At least one previous study 
has suggested such an economic benefi t 
with the use of nurse practitioners. 5 
Whether it indeed was the case in the 
MASTERPLAN study, however, is unclear. 
Patients randomized to intensive care had 
signifi cantly more visits to the health-care 
facility (7.2 vs. 4.7); however, there were 
signifi cantly fewer visits to a nephrologist 
(2.8 vs. 3.7). 3 It is imperative that future 
studies incorporate cost-effectiveness 
analyses to evaluate care models using 
nurse practitioners more comprehensively. 
Alternatively, nurse practitioner care could 
be valuable if they focused on aspects of 
care different from those dealt with by 
nephrologists and / or if their mandate were 
more limited than what was attempted in 
the MASTERPLAN study. Physician visits 
are oft en rushed without insuffi  cient time 
to fully address each aspect of care, and 
nurse practitioners could supplement areas 
where care is beleaguered. 
 In conclusion, the MASTERPLAN 
trial is a very important study, and both its 
successes and its failures will inform deci-
sion making for the inevitable development 
of care models that incorporate physician 
extenders in the care of the high-risk CKD 
population. Th e future success of these care 
models depends on our ability to develop 
high-level evidence to correctly identify 
risk factors to be targeted to mitigate car-
diovascular risk and disease progression, 
determine the correct division of labor, and 
ensure that such care is cost-eff ective. 
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 The risks of vascular access 
 Peter G.  Blake 1 ,  Robert R.  Quinn 2 and  Matthew J.  Oliver 3 
 Fatal vascular access hemorrhage is considered a rare complication of 
hemodialysis (HD). Ellingson  et al. indicate otherwise, and their data 
suggest that it causes 0.4 – 1.6 % of deaths in US HD patients. It is more 
common with grafts than fistulas, and many victims have had previous 
access hemorrhages. The widespread presumption that a fistula is the 
best, and a cuffed catheter the worst, access for HD patients needs 
reassessment, particularly in older, sicker patients. 
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 Most nephrologists with any experience 
of hemodialysis (HD) will have seen cases 
of severe vascular access hemorrhage 
requiring urgent surgical inter vention, 
and some will recall fatalities. However, 
it is likely that most would consider 
this complication a rare cause of death, 
and, until now, there has been little in 
the literature to suggest otherwise. For 
this reason, the paper by Ellingson  et al. 1 
(this issue) is both surprising and impor-
tant. Th e investigators from the Centers 
for Disease Control and Prevention 
became involved when a cluster of such 
deaths was noticed in Maryland, Virginia, 
and the District of Columbia. A regional 
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investigation identifi ed 88 fatal vascular 
access hemorrhage (FVAH) deaths over 
a 6 – year period and noted that only a 
quarter of these cases had been identifi ed 
on Centers for Medicare and Medicaid 
Services (CMS) death reports. Across 
the United States, a startling 1654 deaths 
were identified from CMS data in the 
same period, accounting for 0.4 % of 
all HD deaths. However, if the same 
underestimation had occurred nation-
wide, the true number of HD deaths 
due to FVAH might be more than 6000, 
corresponding to at least 1000 annually 
or 1.6 % of all HD deaths. 
 Th e authors then investigated 88 cases 
in detail and made important observa-
tions. A large majority of the bleeds began 
in the patient ’ s residence and not in the 
dialysis unit. More than half involved 
an arteriovenous graft . Th e mean age of 
the patients was only 64 years, and only 
a very small number of cases appear 
to have been episodes of  ‘ self-harm ’ . 
Compared with case controls, the victims 
were more likely to have had graft s and to 
be long-term HD patients, and, most 
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importantly, they were three times more 
likely to have had an access-related com-
plication within the previous 6 months, 
usually an infection or a previous bleed. 
In a subset of cases in which there had 
been a medical examiner review, 72 % had 
evidence of access erosion, but no infor-
mation is provided about the presence of 
aneurysms, which might have been of 
interest. 
 What conclusions can be drawn from 
this important paper? First, FVAH is not 
a common problem, but we now know it 
is not rare, and hundreds of patients are 
dying from it annually in the United 
States. Second, patients at high risk for 
FVAH are those who have a graft  or fi stula 
that has been infected or has already hem-
orrhaged, and that may be showing evi-
dence of erosion. Such a situation should 
now lead to a specific evaluation of 
the risk of FVAH, and the desirability of 
ligating the graft  or fi stula should at least 
be considered. Survival of the patient is 
more important than survival of the 
access. Also, although this complication is 
rare, HD patients and their families 
should be regularly educated by HD unit 
staff on how to deal with acute access 
hemorrhage. 
 Th is leads us to consideration of the 
broader issue of vascular access in the 
contemporary HD population. Th e past 
decade has seen aggressive efforts to 
increase the use of fi stulas and to reverse 
the growth in the use of cuff ed catheters 
as a form of definitive access for HD 
patients. 2,3 Th is strategy is based on a large 
volume of circumstantial evidence show-
ing a consistent association between use 
of cuff ed catheters and decreased survival 
on dialysis relative to what is seen with the 
use of fi stulas. 4 – 6 Th e presumed major 
mechanism is increased infection rates, 
and, in particular, bacteremia and its 
complications, in patients with catheters. 
 Th ere may, however, be the beginning of 
a reaction to this approach with concern 
being expressed as to whether fi stulas and 
grafts really are the best access for all 
patients. 7,8 In this regard, there is some evi-
dence that needs to be noted ( Figure 1 ). 
 First, failure rates with fi stulas are alarm-
ingly high in contemporary populations. 
In a US multicenter randomized controlled 
trial on the effect of clopidogrel, more 
than 60 % of 877 fi stulas were not adequate 
for dialysis. 9 In a recent Mayo Clinic study, 
there was a 37 % primary failure and a sub-
sequent 11 % secondary failure rate, while 
21 % of patients had signifi cant postopera-
tive complications. 10 Such failure rates 
would be unacceptable with most other 
types of surgery. Second, a sequence of 
failed fi stula construction, repeat attempts 
that may or may not be successful, diffi  -
culty with needling, requirement for sal-
vage procedures, and all the associated 
pain and inconvenience can be very diffi  -
cult and unpleasant, especially for patients 
who may already have an impaired quality 
of life and multiple comorbidities. All this 
may not be justifi able in patients with a 
limited life expectancy. 
 Th e alternative approach of using a syn-
thetic graft  has a higher success rate and 
facilitates earlier use but also has a higher 
and perhaps unacceptable requirement 
for subsequent interventions and proba-
bility of eventual failure. 7 Furthermore, 
both fi stulas and graft s may also be associ-
ated with other problems, such as aggra-
vation of cardiac failure; steal syndromes, 
including overt hand ischemia; pulmo-
nary hypertension; and, as Ellingson  et al. 
have now shown, FVAH ( Figure 1 ). 1,8 
 Of course, all these risks have to be 
accepted if those associated with catheter 
use are clearly greater. Two large US stud-
ies have reported that adjusted mortality 
rates for incident HD patients with cath-
eter access are 1.70 and 1.49, respectively, 
relative to those with a fi stula. 4,5 Moist 
 et al. report that incident catheter use in 
Canada is associated with a remarkable 
sixfold increase in the mortality rate com-
pared with fi stula use. 6 Th ese are observa-
tional studies, however, and there is always 
the reservation that adjustment for base-
line comorbidity and other characteristics 
cannot be complete. In an era in which 
most North American patients initiate HD 
via a cuffed catheter, the presence of a 
functioning fi stula is surely a marker of a 
patient ’ s exceptional health and adherence, 
and so all or even most of the superior out-
come may not be related to the fi stula itself. 
Also, catheter use is inevitably associated 
with acute illness and late presentation for 
dialysis, factors that are in turn associated 
with high mortality and that may be dif-
ficult to adjust for. In other words, the 
association of catheters and mortality may 
not be causal. Studies have not shown all 
the excess mortality with catheters to be 
infection-related, and, in any case, there is 
evidence that, with increased experience 
and better preventative strategies, catheter-
associated bacteremia rates are falling 
impressively — to as low as one to two every 
3 years in a recent trial. 11 
 Notwithstanding all this, a fistula 
appears to be the access of choice for 
younger and healthier HD patients. How-
ever, for the large number of older, sicker 
patients with risk factors for fi stula failure 
and associated complications and with 
shorter life expectancy, the risk-to-benefi t 
ratio changes and it may be reasonable to 
use a catheter as defi nitive access. Perhaps 
it is to time to discard the dogma that has 
long dominated this area and to propose 
a randomized controlled trial of fi stulas 
versus cuff ed catheters in the high-risk, 
older, frailer HD population, which is 
such a prominent feature of North Amer-
ican HD units. Such a trial would look 
at not only patient survival but also qual-
ity of life and degree of pain; access infec-
tions and other complications, including 
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 Figure 1  |  The advantages and challenges of the major forms of vascular access. 
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thrombosis and hemorrhage, cardio-
vascular consequences, and numbers 
of interventions required; and, not least, 
cost. Th e results might be surprising. It 
would be far from unprecedented for a 
dogmatic belief about how to care for 
dialysis patients to be contradicted by a 
randomized trial. 
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 The Alternative Iranian model of 
living renal transplantation 
 Francis L.  Delmonico 1 
 The experience of the Iranian model should be carefully considered by 
those who suggest a pilot trial of a regulated market in organ sales. 
Mahdavi-Mazdeh ’ s candid report makes clear that a fixed price as the 
basis of regulation is not possible. Iran is proceeding with an 
independent program of deceased organ donation in cities such as 
Shiraz. Mahdavi-Mazdeh ’ s report is encouraging for the prospect of a 
revitalized expansion of deceased donation. 
 Kidney International (2012)  82, 625 – 626.  doi: 10.1038/ki.2012.247 
 Mitra Mahdavi-Mazdeh is a highly 
regarded physician internationally who 
represents the best of Iranian medicine. In 
this issue of  Kidney International , 1 
Dr Mahdavi-Mazdeh presents a candid 
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and comprehensive review of the Iranian 
model of living renal transplantation. Th e 
Iranian living-donor program has spanned 
two decades, with more than 20,000 ven-
dors participating. 1 Dr Mahdavi-Mazdeh ’ s 
conclusions are poignant and sobering. 
The process of identifying an Iranian 
vendor for a potential kidney transplant 
recipient ultimately occasions a tense 
fi nancial bargaining between the donor 
and the recipient that escapes regulatory 
control. The vendor wants to be paid 
more; the recipient wants to pay less. Th e 
vendors want more because they are poor; 
the recipients want to pay less because 
they may not have the money. 
 Th e experience of the Iranian model 
should be carefully considered by those 
who suggest a pilot trial of a regulated 
market in organ sales. Th is candid report 
makes clear that a fi xed price as the basis 
of regulation is not possible. Th e vendor 
demands more money than is allotted 
by the government ’ s fixed price, in 
what Mahdavi-Mazdeh describes as a 
 ‘ confrontation. ’ And although the fi nal 
interaction may be perceived as broker 
free, the introduction of the recipient to 
the unrelated donor is not, with shopping 
at the 137 kidney-foundation outlets 
throughout the country. 
 Mahdavi-Mazdeh, like other Iranian 
colleagues, rationalizes these realities by 
asserting that the model  ‘ has enabled most 
of the Iranian kidney transplant candi-
dates, irrespective of socioeconomic class, 
to have access to kidney transplantation. ’ 
But the program is not just about recipi-
ents. Th e experience of Iran and the rest 
of the world has clearly shown that ven-
dors are poor, hapless, jobless, indebted, 
and largely destitute. It is this social condi-
tion that compels the vendor to sell a kid-
ney. Th e male – female ratio of 1.6 among 
Iranian vendors is in keeping with the 
published vendor demographics. It is 
exploitation of the poor that has enabled 
most Iranian kidney transplantations 
over the past two decades. Whether a 
vendor resides in Iran or is Pakistani or a 
Sudanese refugee or a Filipino, the funda-
mental unethical aspect is the same — it is 
a victimization of the poor. 
 Mahdavi-Mazdeh acknowledges that 
the Iranian model has, regrettably, pro-
vided little information about such a large 
nephrectomized patient population. She 
has carefully reviewed the literature to cite 
studies showing a less than 1 % risk of 
kidney donors ’ developing end-stage renal 
disease, but none of these references is 
from an Iranian experience. Not cited 
is the reported health status of vendors 
from neighboring Pakistan. Many of these 
Pakistani vendors were bonded laborers, 
some jaundiced, some with inadequate 
kidney function, and some with stone 
